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Abstract 
 
 
This paper seeks to explain why some pharmaceutical companies are observed to 
withdraw their products before patents are expired and simultaneously introduce new 
patented (competing) products. Given the specific nature of drug markets, the companies 
in fact increase the entry cost of the potential generic drug manufacturers and thereby 
lessen competition for new drugs. The paper determines the optimal date of withdrawing 
the product and studies comparative static effects of the change of parameters underlying 
the model. 
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1. Introduction 
International patent rules have come into existence after the Uruguay Round of 
Multilateral Trade Negotiations under the GATT and are being enforced by the World 
Trade Organization (WTO). Before the GATT resolution, the norms and standards of 
intellectual property protection in the international context were governed by the World 
Intellectual Property Organization (WIPO). The WIPO, as contrary to WTO, had neither 
enforcing power nor dispute settlement mechanism; it gave the countries flexibility to 
design their own patent rules, and choose the coverage of patentability. As a result, there 
were various products like agricultural machinery, fertilizers, chemical products, food 
products, and pharmaceutical products, which were excluded from patenting in many 
developing countries. But the GATT based patent system has called for a uniform patent 
protection for all products including pharmaceuticals, genetically engineered organisms, 
plants and animal varieties for 20 years. 
            This has given rise to acrimonious debate between the developed and the 
developing countries.1 In the present paper the issue at hand is pharmaceutical industry. 
In fact, the proposal requiring product patents for pharmaceutical innovations has been 
one of the most sensitive issues. This has evoked a considerable debate and differences of 
opinion among the economists and industrialists. While the developing countries think 
that the medical discoveries should be available free of patents, the developed countries 
call for a stronger international patent protection so as to ensure high prices and high 
profits in the pharmaceutical industry, given industry’s uniquely high and risky 
expenditures on research, development and introduction of new products.2  
             In the context of pharmaceutical industry, problems usually dealt with in the 
literature reflect the concern over the impact of patent rights on the prices of generic 
products, rates of innovation, and welfare of the trading nations. For this literature one 
may look at, for instance, Frank and Salkever (1992), Grabsowski and Vernon (1992), 
Nogues (1993), Watal (1996) and Lanjouw (1997). However, the present paper highlights 
                                                           
1
 Already there is a large literature focusing on the north-south debate on IPRs. Interested readers may look 
at Chin and Grossman (1991), Maskus (1990), Diwan and Rodrik (1991), Deardorff (1992), Aoki and Prusa 
(1993), Helpman (1993), Taylor (1994), Grinols and Lin (1997), Yang (1998), Marjit and Beladi (1998), 
Kabiraj (2000), Grossman and Lai (2004), etc. 
2
 Scherer (2002) discusses the question of whether global welfare is higher under uniform pharmaceutical 
patent standards or with free riding. 
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a different problem. This is motivated from the survey results of Dutta (2003). It is found 
that some pharmaceutical companies withdraw patented drugs before the expiry of patent 
period and simultaneously introduce a new patented drug. Though this seems to be 
strange, as it cuts back the initial period of monopoly for the patent holder, we argue that 
this type of strategy has a deeper implication. In particular, such a strategy adversely 
affects entry of the potential firms who wait to introduce the generic drug once the patent 
period is over, and hence it has implication for drug prices.3 
             Entry in the drug market depends on the following consideration. The traditional 
system allowed process patenting and encouraged inventing around. This enabled the 
firms to develop commercial production capabilities for on-patent drugs before patent 
expiry and then compete in the world market as soon as the patent elapsed. Market entry 
by generics was limited only to the extent they would have to take pioneer’s tests before 
gaining market approval. Thus the originator had to face a tough challenge from the 
imitators even during the patent period. And after expiry of the patent, its profits drop 
substantially due to competition from the generic substitutes. In the new patent system, 
process patenting as well as compulsory licensing has been almost scrapped. Hence the 
innovator, the patentee enjoys almost monopoly for the whole stretch of the patent 
period.  
             Theoretically, even under the new patent system, pioneer’s profits should drop to 
an insignificant amount after the patent expiry with the entry of generics. In practice, this 
never happens because of the peculiar nature of the pharmaceutical products as a whole. 
Typically, pharmaceuticals are cited as an example of first-mover advantage. First- 
movers have natural product differentiation advantages that permit them to charge higher 
prices and retain substantial market shares (see Conrad (1983) and Schmalansee (1982), 
and Scherer and Ross (1990)). There is a strong brand loyalty in pharmaceuticals for 
innovative brands over generic competitors. Once physicians gain experience with a new 
drug during its period of patent exclusively, then even when patents expire and cheaper 
substitutes become available, many physicians might remain insensitive to the lower-
price opportunities, and therefore they continue to prescribe the branded product. In 
                                                           
3
 For the literature on entry deterrence see, in particular, Dixit (1980), Milgrom and Roberts (1982), and 
Salop and Schiefman (1983). 
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pharmaceutical industry, the consumers and the consumption decision-makers (that is, 
physicians) are not the same, and sometimes the consumers are not the ultimate 
contributors due to existence of the third party reimbursement schemes. The combination 
of all these factors makes demand for the branded product stronger and less elastic.  On 
the supply side entry of the potential firms is restricted to the extent they will have to 
incur costs on getting market access in the post-patent period. There are evidence 
showing that after patent expiry the price of the branded product has gone up and that 
there has been only marginal market share gain by generic entrants even several years 
after patent expiration (see, for instance, Statman (1981), Frank and Salkever (1992), 
Grabowski and Vernon (1992), and Hollis (2005)).4     
  This paper refers to the situation when the patent holder intends to deter by 
means of withdrawing the existing patented product from circulation and then 
introducing a new patented substitute. The withdrawal date is optimally chosen by the 
incumbent and is chosen earlier than the expiry date of the patent. The role of the 
prescribing medical practitioners is very important in this context since their prescriptions 
in a way determine the marketability of the medicines. The new drug is introduced with 
the pretext that it has new and interesting characteristics. It gets prescribed before the 
generic substitutes of the old drug have a chance to appear, since the patent period for the 
old drug is yet not over. Since doctors often are not fond of prescribing drugs that have 
gone out of fashion, the potential entrants of the generic drugs find it tough to compete 
after entry since the original drug itself is out of circulation for some time. There is no 
taker for their generic substitute and a newer form of the original drug already reaches the 
market. This is the case where deliberate withdrawal of patented drug even before the 
expiry of the patent period leaves the potential entrants at a disadvantage and acts as an 
entry deterring strategy.   
  The empirical support of our theory is drawn, as mentioned earlier, from the 
survey reported in Dutta (2003). For a molecule named Nitrofurantoin, initially the 
normal tablet was patented for twenty years. Close to the expiry, a new formulation 
naming, Vincristine, was introduced and a patent was again taken. Next, before 
                                                           
4
 Indian case shows that in 1998 patented drugs constituted 84.7 % market share in anti-hypertensive, 
70.3% in Quinolones and 56.7% in anti-ulcerants. 
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completing the term of twenty years, a new patent was taken on the solution form of 
Vincristine, saying that the new form is even more stable. The original drug was 
withdrawn while marketing the new drug. Another example is Cyclosporin. Close to the 
expiry of the patent, the patentee introduced a new micro-emulsion form of the drug. 
Doctors are usually not interested in prescribing drugs which are not vigorously 
marketed. The cause behind this is that they derive the knowledge of new drugs from the 
medical representatives, who constitute the backbone of pharmaceutical marketing. A 
survey on doctors from Calcutta and Bolpur, a district town in West Bengal, India, 
revealed that sixty per cent of the doctors surveyed collected information about new 
drugs from the representatives, though they seldom received any detailing about the 
chemical and biological characteristics from them. The pharmaceutical companies stress 
on heavy marketing of new molecules. If they decrease the marketing expenditure in the 
post patent expiry period, the market share of those drugs fall fast because the memory of 
the doctors is short. On the other hand, if the firms find that there is no new generation 
substitute in the pipeline, they increase promotional expenditures on them. This may 
increase their market share even after expiry of the patents. For example, market shares 
of Sulphamides and anti-depressants increased after patent expiry in early 70’s due to the 
boost up in promotional expenditures (Slatter, 1977).  
   We construct a simple dynamic model of an entry game capturing the above 
facts. The key feature of the model is that early withdrawal of the patented drug increases 
the entry costs of the potential entrants with generic substitutes. Although we do not 
model the strategy of the prescribing doctor explicitly, early termination implies that the 
drug is out of circulation and the entrants have to spend more to influence the doctor to 
prescribe an out-of-circulation drug. But early termination is costly for the incumbent in 
the sense that it has to forego patent protected profit from the old drug and have to 
introduce a new drug early. Such a trade-off determines the optimal termination period.  
The termination date is sensitive to certain basic parameters of the model, such as the cost 
of introduction and promotion of the new drug, the length of the patent period etc.   
Before we go to the next section, let us summarize the key forces driving our 
result. First, the existence of patent prevents the imitators to market the product during 
the patent period. And second, given the behavior of the doctors, the incumbent 
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strategically withdraws its product from the market before its patent expires and 
simultaneously introduces a new patented product. This behavior increases entry costs of 
the generic producers and alters market competition in incumbent’s favor. 
  The paper is laid out as follows. In the second section we discuss the model and 
the results. The third section concludes. 
 
2. Model and Results 
 
In this section we provide a model to show that the incumbent, the originator of a drug, 
will introduce a new competing drug before the patent of its earlier generation expires. 
Imitators can enter the market with generics of a drug only after its patent period is over. 
We focus on the stationary equilibrium where the patent holder withdraws the new 
patented drug before the old patent expires. 
           Let T  be the length of patent of a drug available from the date it is introduced in 
the market. Then we are concerned with an equilibrium when the incumbent introduces a 
new substitute drug t  years before the expiry of patent of its earlier generation; ],0[ Tt ∈ . 
We further show that introducing the new drug after the expiry of the patent will never be 
optimum. To make the analysis simple we assume zero discounting rate. 
          Let D(0) denote the current generation drug. Then D(-s) denotes the s -generation 
earlier drug and D(r) is the drug to be introduced r  generations later. We assume that 
demand for drugs over time remains unchanged and that the newer version of drugs will 
have no market demand effect.5 However, doctors will be more prone to prescribe the 
latest generation drug. In other words, the older generation drugs will have lower market 
share, as if, older generation drugs become obsolete in the minds of the doctors. To make 
the structure simple, we further assume that when the latest generation drug (which is 
presently protected by a patent) competes with the generics of older generations, only the 
last generation generic will survive and all older generation generics will have zero 
                                                           
5
 In the paper we assume that the patented drug and the generics are perfect substitutes (in their 
composition and efficiency), but the doctors are more prone to prescribe the latest generation possibly 
presuming that this is more effective and/or safer. Alternatively, the new drug may have a strong brand 
loyalty and therefore the physicians may easily prescribe such a drug. We however, deliberately abstract 
from the situation when firms produce vertically differentiated products and consumers are willing to pay a 
higher price for a better quality. The assumption of `no demand shift effect’ facilitates us to focus purely on 
the entry deterrence strategy of the incumbent.  
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market shares. The doctors while prescribing the drug do not take into older generation 
generics except the one in the recent past. Thus when D(0), D(-1) and D(-2) compete in 
the market place, D(-2) will have no positive market share, and in competition between 
D(0) and D(-1), the drug D(0) will have a larger market share. 
          Think of the period when D(0) is not yet introduced but patent of D(-2) has 
expired. Then D(-1), which is now under patent protection, will compete with generics of 
D(-2). Let the flow of gross payoffs of the originator of D(-1) and that of each entrant 
producing generics D(-2) be )(nB  and )(nG , respectively, which are decreasing 
functions of the number of entrants ( n ); therefore 0)( <′ nB  and 0)( <′ nG .  
          Consider now the period after introduction of D(0). By our assumption, D(0) is 
introduced t  years before the expiry of patent of D(-1). So these t  years the patented 
D(0) will compete with D(-2) generics. Note that during first t  years after launch of D(0), 
the drug D(-1) cannot be imitated. Let )(nA  and )(~ nG  be the flow of gross payoffs of the 
patentee of D(0) and each D(-2) generic producer, respectively. Given the story 
underlying our structure, it is then natural to assume that )()( nBnA > and )(~)( nGnG > . 
For our results, however, neither of these conditions is necessary, but these justify why   
very old generation drugs will not survive competition. 
            But once t  years are over after D(0) is launched, generics of D(-1) will enter 
(because by this time its patent is expired). Then by assumption, producers of D(-2) 
generics will cease to operate. Then a next generation drug, D(1), will be launched again 
t  years before the expiry of patent of D(0). Therefore, D(0) and generics of D(-1) will 
compete for tT 2− years. 
            This framework suggests that any generic producer will enjoy a flow of gross 
profit )(nG  for tT 2−  years before the next generation drug is introduced and )(~ nG  for 
t  years after the new generation drug is introduced. Similarly, for any new innovation, 
the incumbent will get a flow of gross payoff )(nA  for the first t  years of the product and 
)(nB  for the next tT 2−  years. It is further understood that for 2Tt ≥ , 0)( =nB  and 
0)( =nG . 
            Since we are assuming away any demand effect of a new drug, the payoff 
structure of the incumbent and the generic producers will remain the same as above. In 
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other words, the same scenario will repeat every time after a new generation drug is 
introduced. The sequence of launching new drugs is depicted in Figure 1. 
           We shall now introduce the cost side. Assume that there is a cost to introduce a 
new drug by withdrawing the existing patented drug from the market before the patent 
expiry. This may also include the cost of advertising and marketing of the new drug. 
When the drug is introduced t  years before the expiry of patent of its earlier generation, 
the corresponding cost is given by the function: 
      )(tZ  with (i) 0)( =tZ  for 0≤t , (ii) 0 0)( >∀>′ ttZ  and (iii) 0)0( =′Z               (1) 
This cost is increasing in t , and is zero if the product is introduced after the expiry of 
patent of its earlier generation. 
          Similarly, the generic producers face an entry cost which directly depends on the 
length of the period the product goes out of the market before any generics can be 
introduced. This is given by  
          )(tE  with (i) EtE =)(  for 0≤t , and (ii) 0 0)( >∀>′ ttE                                 (2) 
        Since the new product is to be innovated, it involves an R&D cost. Let the cost be 
given by the function  
      )(tI  with (i) ItI =)(  for 0≤t , (ii) 0 0)( >∀>′ ttI  and (iii) 0)0( =′I                (3) 
This tells us that the earlier the product is innovated, the larger the cost of innovation is. 
          Given the structure of the model, we are now in a position to find the optimal 
number of entrants producing generic drugs and the optimal time of introducing a new 
product. If n  generic producers enter the market, each such firm’s net payoff becomes 
                                             )()(~)()2( tEnGtnGtT −+−  
Then the optimal n  is solved from  
                                          )()(~)()2( tEnGtnGtT =+−                                                (4) 
Eqn. (4) solves (.)n  as a function of t . Given the restrictions, 6  we must have 
0 0)( >∀<′ ttn  and *)0( nn =  with 0 )(* >∀> ttnn . This is quite intuitive. As t  goes 
up, on one hand the entry cost goes up, and on the other the period of possible operation 
of each generic drug is shortened. Therefore, there will be lower number of entrants. 
 10 
          Now, given )(tn , define 
                                 ))(()( tnAtA =  and ))(()( tnBtB =                                            (5) 
Since 0},,{ <′′′ nBA , we must have 0)( >′ tA  and 0)( >′ tB  for all t .  
          The incumbent’s problem is 
                                C(t)-R(t)V(t) max
],0[
=
∈ Tt
                                                              (6) 
where,  
                           (t)B2t)-(T(t)AtR(t) +=  and )()()( tItZtC +=  
           To see that the above problem has an interior solution, note that *),()0( nBTR =  
IC =)0( , 0)( =TR  and 0)( >TC . Therefore, 0)( <TV , and it is reasonable to assume 
0)0( >V , that is, 
                                       0*)( >− InBT                                                                     (7) 
This tells that the R&D cost associated with an innovation will be fully recovered by the 
existing patent system. Hence, 
                                        0)(| ><∃ tVTt                                                                 (8)  
          Now to ensure that the optimal t  is indeed positive, consider the first order 
condition of the maximization problem (6), i.e.,  
                                     
Ior
tCtRtV
′+′=′+′+
′
−
′=′
ZB2-B2t)-(T AtA  ,
)()()(      
                                (9) 
If *t  maximizes )(tV , then 0* >t  if and only if 0)0( >′V , that is, 
                                        0*)(2)0(*)( >−′′ nBnnBT                                              (10) 
Eqn. (7) and (10) together ensure that 
                                        )(0)0(*)( TVVtV >>>                                                    (11) 
          Now we show that introducing the new drug at a date after the expiry of patent of 
the earlier generation drug will not be optimal. To do so, suppose that the innovation is 
introduced τ  years after the expiry of patent of its earlier generation; 0>τ . The 
sequence of introduction of new drugs is shown in Figure 2. 
                                                                                                                                                                             
6
 We have, )(1
T
EGn −=∗  and 0
~)2(
~2)( <
′+′−
′+−
=′
GtGtT
EGG
tn . 
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          As the Figure 2 shows, here the number of generic entrants ( nˆ ) will be more than 
*n , i.e., *ˆ nn > , because the patent of the existing drug expires before the current 
generation drug is introduced and hence entrants have low cost of entry. Moreover, these 
firms compete with the current generation for a period longer than T . 
          Therefore, the innovator of a drug will derive a flow of gross payoff )ˆ(nB  during 
the patent period; *)()ˆ( nBnB < . And once its patent is expired, next τ  years it will 
compete with its generics, and hence its payoff may be assumed to drop to zero due to 
entry of large number of generic producers. Hence the net payoff that the innovator is 
expecting to derive from introducing a drug τ  years after the patent expiry of its earlier 
generation is: 
                         IBTInBTV −=−+= )(ˆ0.))(ˆ( )(ˆ ττττ                                             (12) 
Comparing (7) and (12), we have 
                                         0  )(ˆ)0( >∀> ττVV                                                          (13) 
We are now in a position to write the main result of our paper. 
Proposition: It is optimal for the originator of a drug to introduce a new competing drug 
before the expiry of patent of its earlier generation. 
Proof: Results (11) and (13) together imply that )(ˆ)0(*)( τVVtV >> , and hence the 
result.                                                                                                                         QED 
           The result can be explained as follows.7 If the new drug is introduced after the 
period of patent expiry of the earlier generation, then it will face more competition from 
the entrants producing generic drugs of the earlier generation, because generic entrants 
now face a lower cost of entry, and once patent of the current drug expires, the generics 
of the current generation drug enter. This will result in a drop of revenue almost to zero. 
           On the other hand, when the new drug is introduced at an earlier date before the 
expiry of patent of its earlier generation, the innovator, by doing so, successfully 
increases entry cost of the potential generic entrants. Although the innovator itself incurs 
some additional costs of innovating and introducing the product earlier, under some 
conditions this strategy is profitable. To see the effect of an increase in t  on revenue of 
                                                           
7
 The incumbent perhaps has an additional option, namely introducing its own generics. It has, however, 
two opposing effects: it increases incumbent’s profits to the extent it saves entry cost for introducing its 
generics, but it reduces profits to the extent additional competition dissipates profits. 
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the innovator, note that as t  goes up, the length of operation of the innovator with this 
drug is shortened to that extent, and hence there is some loss of revenue. On the other 
hand, during the period it operates, it faces less competition from generics of earlier 
generations. These two opposite forces give the necessary trade-off and determine the 
optimal 0>t .  
 Before we go to the comparative static results, a number of related issues may be 
discussed briefly. One such issue is the price caps on drugs. The innovating firms 
sometimes engage in this kind of practice as a means for extending patent period with 
minor improvements. This is also a reason that drugs may be introduced earlier. Since we 
are considering market-determined outcomes, we are not looking at price caps. Moreover, 
such a possibility will not hold with the homogeneous good case as in our set up. Second, 
in our model both the incumbent and the generic producers play a simultaneous move 
game at the production stage. One may then think of a scenario where the generic 
producers have the first mover advantage. However, from the innovator’s point of view 
less competition (due to raising entry cost induced by early patent termination) is always 
good and hence our basic result should still hold. Third, our model is entirely 
deterministic and there is no information problem. In reality, there can be uncertainty 
regarding the patent termination period. The brand producers may not have a perfect 
knowledge of exactly when the generics will come in.  But note that in our model the 
generic suppliers will never delay their entry beyond the patent period and will enter right 
after the patent period is over, because delay will not give them extra pay off. The generic 
producers can anticipate that there will be a new brand. But they can’t do much about it; 
they will have to fight armed with the generics of the old brand, given that the new brand 
is protected by a patent. Finally, we should mention that our paper grows out of empirical 
evidence in the pharmaceutical industry where the firms are observed to effectively 
terminate drugs before the patent period is over. We have shown that such an outcome is 
consistent with rational strategic action of the innovator. While the empirical evidence 
generated out of a field based survey provides the initial motivation for the work, and this 
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appears to be appealing, but the key consideration in the paper is that the innovator can 
take some strategic action that makes entry of the generics difficult.8  
 
Effects of a change in T  
          For comparative static analysis let us assume that *t  is a unique and stable 
equilibrium within the domain satisfying (7) and (10). From Eqn. (4) we shall get n  as a 
function of t  and T , i.e., ),( Ttn  with 0<tn  and 0>Tn . Then Eqn. (9) will solve for 
)(* Ttt =  satisfying CRt ′=  and 0<′′−≡∆ CRtt . Hence when T  changes, it affects *t  
directly (when n  and tn  remain unchanged) and indirectly through the change of n  and 
tn . Therefore, from the condition CRt ′= , we shall get: 
                                ][1* tTtnTtntT nRnRRdT
dt
t
++
∆−
=                                                (14) 
where, 
            CnBnBtTnBtTnAtnAtnA tttttttt ′′−′−′′−+′−+′′+′+′=∆ 4)2()2(2 22  
          ttT nBR ′=  
          BnBtTnAtAR tttn ′−′′−+′′+′= 2)2(  
          BtTAtR
ttn
′
−+′= )2(  
          It is clear that 0>tTR . Therefore, the direct effect of a change in T  is positive, i.e., 
an increase in T  will lead to an increase in *t . Since a priori we cannot make any 
conclusion on the sign of tTn , to make it simple we may assume that 0=tTn , i.e., a 
change of T  will lead to a parallel shift of ),( Ttn  function. Moreover, it is not 
unreasonable to assume that if n  goes up, it leads to a downward shift of the tR  curve,
9
 
hence assume 0<tnR . Under this assumption the indirect effect of a change in T  is 
negative. Hence the net effect of a change of T  on *t  depends on two opposing effects. 
                                                           
8
 For instance, Hollis (2003) and Kong and Selden (2004) have shown that an introduction of a pseudo-
generic into the market by the incumbent may act as entry deterrence or delay entry of independent 
generics. And Kamien and Zang (1999) think that pre-emptive pseudo-generics are a form of virtual patent 
extension. 
9
 We may generally presume that 0,0 >′′>′′ BA . Then the sufficient condition for 0<tnR  is 
02 ≤′−′ BA . 
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When the direct effect dominates the indirect effect, *t  will go up as T  increases. Then, 
if further, 0<tTn , this will reinforce our conclusion.
10
 
           If there is a shift of E  function, it has only indirect effect --- *t  will change 
through the shift of ,.)(tn . However, if there is a shift of either I  function or Z  function, 
to the extent it results in a shift of )(tC ′  function, *t  will be affected. For instance, if 
)(tC ′  shifts up, *t  must fall. 
 
3. Conclusion 
A strong argument in favor of granting patent rights has to do with encouraging 
innovations since the monopoly profit of the innovator is protected over the patent period, 
usually for twenty years. We argue that given a guaranteed patent period, pharmaceutical 
firms can also engage in further anti-competitive and entry deterring strategies by 
withdrawing the patented drug before the expiry of the patent period. Our analysis is 
based on some empirical evidence where early withdrawal of the drug makes the future 
generics less effective as competing products. Although the doctors’ role is crucial in the 
analysis, we have not explicitly modeled doctors’ behavior because it is unlikely to alter 
the qualitative result of the model. We highlight the role of prescribing doctors who are 
likely to be influenced by the persuasion of the innovating firm. We develop a simple 
dynamic model to capture the effect of such an interesting entry-deterring strategy.  
 Our paper opens up the possibility of an interesting policy question. Should the 
organization such as the FDA allow the drug companies to withdraw the patented drug 
before the expiry of the patented period and to introduce a new drug earlier than what is 
expected? The generic substitutes which are supposed to come up right after the patent 
period is over, will be in a disadvantageous position if the doctors are somehow 
convinced of the “limitations” of the drug the generics are likely to substitute. If the 
producer of the existing patented drug A, reveals an `adverse side effect’ and uses this as 
an excuse to prematurely introduce the new drug B, the generic substitute of A will be in 
a bad shape. We argue that the drug manufacturer/innovator might have all the incentive 
                                                           
10
 Since a low T  means, 0* =t , the strategic mechanism highlighted in the paper is provided by too high 
a length of the patent. 
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in the world to use such `revelations’ as a profit-increasing strategy.   However, the 
problem is that there is no obvious way to decipher the fact that whether the existing drug 
should really be replaced, because there is a sudden discovery of an unanticipated side-
effect, or something needs to be improved upon immediately. Our paper proposes to take 
up this particular issue, the behavior of prescribing doctors, `influence-fee’ to induce the 
doctors to prescribe the new drug etc., as inputs for further research. But at the end our 
point that strategic withdrawal of patented drug can lead to anti-competitive outcome, is 
quite a fresh insight so far as the economics of patent is concerned.  
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Figure 1: Sequence of introducing new drugs before expiry of patents 
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Figure 2: Sequence of introducing new drugs after expiry of patents 
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